GSK announced today that it has bought GlycoVaxyn AG, a Swiss specialty vaccine biopharmaceutical company, for $190 million.
A research-based pharmaceutical and health care company, GSK previously acquired minority stakes in GlycoVaxyn in 2012 when the two companies formed a scientific collaboration.
GlycoVaxyn, originally a spin-off from ETH Zurich, was established in 2004. The company’s specialty is developing innovative bioconjugate vaccines for bacterial infections. It is estimated to be worth $212 million.
The agreement grants GSK a small number of vaccines in the early stages of development. These vaccines fight against common bacterial infections, including Staphylococcus aureus, Shigellosis, Pseudomonas and pneumonia.
Currently, GSK and GlycoVaxyn leadership teams are collaborating to create ways that will give GlycoVaxyn autonomy without compromising the support and scale of GSK.
"This is an exciting opportunity to expand our research efforts to develop a new generation of vaccines for common and severe bacterial infections, for many of which there are currently no effective vaccines,” Dr. Moncef Slaoui, chairman of vaccines at GSK, said. “It reinforces our commitment to seek out and invest in great science, and complements our proposed transaction with Novartis, which will strengthen our leading position in vaccines."